Prognostic marker analysis in pediatric intracranial ependymomas

被引:0
作者
Roger E. McLendon
Eric Lipp
Diane Satterfield
Melissa Ehinger
Alan Austin
Debra Fleming
Kathryn Perkinson
Michaela Lefaivre
David Zagzag
Benjamin Wiener
Sri Gururangan
Herbert Fuchs
Henry S. Friedman
James E. Herndon
Patrick Healy
机构
[1] Duke University School of Medicine,Department of Pathology
[2] Duke University School of Medicine,Department of Surgery
[3] Duke University School of Medicine,Department of Pediatrics
[4] New York University,Department of Pathology
[5] Duke University School of Medicine,Department of Biostatistics
来源
Journal of Neuro-Oncology | 2015年 / 122卷
关键词
Pediatric; Ependymoma; Immunohistochemistry; Vascular endothelial growth factor; MIB-1; Carbonic anhydrase IX;
D O I
暂无
中图分类号
学科分类号
摘要
Histologic grading methods dependent upon H&E staining review have not been shown to reliably predict survival in children with intracranial ependymomas due to the subjectivity of the analytical methods. We hypothesized that the immunohistochemical detection of MIB-1, Tenascin C, CD34, VEGF, and CA IX may represent objective markers of post-operative survival (Progression Free and Overall Survival; PFS, OS) in these patients. Intracranial ependymomas from patients aged 22 years or less were studied. The original histologic grade was recorded, H&E sections were reviewed for vascular proliferation status, and immunohistochemistry was used to determine MIB-1, Tenascin C, CD34, VEGF, and CA IX status. Based upon the World Health Organization (WHO) grading system, 3 Grade I, 18 Grade II and 9 Grade III ependymomas were studied. Median follow-up time was 9.0 years; median PFS was, 6.1 years. Original WHO grade did not correlate with PFS or OS. Peri-necrotic CA IX localization correlated with PFS (Log rank = 0.0181) and OS (Log rank p = 0.0015). All patients with a CA IX ≤ 5 % total area localization were alive at last follow-up. Perinecrotic CA IX staining was also associated with vascular proliferation (p = 0.006), though not with VEGF expression score. MIB-1 labeling index (LI) correlated with OS (HR 1.06, 95 % CI 1.01, 1.12) and PFS (HR 1.08, 95 % CI 1.02, 1.14). MIB-1 LI and perinecrotic CA IX individually correlated with PFS. The effect of perinecrotic CA IX remained when grade was added to a Cox model predicting PFS. Immunodetection of CA IX and MIB-1 expression are predictive biomarkers for survival in children with posterior fossa ependymomas. These markers represent objective indicators of survival that supplement H&E grading alone.
引用
收藏
页码:255 / 261
页数:6
相关论文
共 180 条
[1]  
Tihan T(2008)The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors Mod Pathol 21 165-177
[2]  
Zhou T(2013)Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system Brain Pathol 23 584-594
[3]  
Holmes E(2009)Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis Pathol Oncol Res 15 605-614
[4]  
Burger PC(2008)Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker Histopathology 53 39-47
[5]  
Ozuysal S(2006)Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas Cancer 106 388-395
[6]  
Rushing EJ(1998)Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma Am J Surg Pathol 22 816-826
[7]  
Raghunathan A(2005)Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival Acta Neuropathol 109 211-216
[8]  
Wani K(2006)Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Res 66 7843-7848
[9]  
Armstrong TS(2008)Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan J Clin Oncol 26 271-278
[10]  
Vera-Bolanos E(2004)Algorithm for the standardized assessment of vascular patterns in glioblastoma specimens Clin Neuropathol 23 238-240